You are here

Catalist-listed SeD claims its two compounds can block Covid-19 infection

CATALIST-LISTED Singapore eDevelopment (SeD) on Tuesday said that its US subsidiary, Impact BioMedical, has tested two compounds that can successfully inhibit the infection by the Covid-19 virus.

Results from Impact BioMedical's recent molecular-docking studies indicate that compounds '...

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes